Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) EBIT Margin: 2012-2025

Historic EBIT Margin for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to -121.56%.

  • Enanta Pharmaceuticals' EBIT Margin rose 8282.00% to -121.56% in Q3 2025 from the same period last year, while for Sep 2025 it was -130.65%, marking a year-over-year increase of 4927.00%. This contributed to the annual value of -130.65% for FY2025, which is 4927.00% up from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported EBIT Margin of -121.56% as of Q3 2025, which was down 17.83% from -103.16% recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' EBIT Margin ranged from a high of -103.16% in Q2 2025 and a low of -221.70% during Q1 2023.
  • For the 3-year period, Enanta Pharmaceuticals' EBIT Margin averaged around -166.61%, with its median value being -164.32% (2025).
  • In the last 5 years, Enanta Pharmaceuticals' EBIT Margin crashed by 10,453bps in 2021 and then surged by 8,282bps in 2025.
  • Quarterly analysis of 5 years shows Enanta Pharmaceuticals' EBIT Margin stood at -109.99% in 2021, then crashed by 1,727bps to -127.25% in 2022, then tumbled by 6,652bps to -193.78% in 2023, then soared by 5,496bps to -138.82% in 2024, then skyrocketed by 8,282bps to -121.56% in 2025.
  • Its EBIT Margin was -121.56% in Q3 2025, compared to -103.16% in Q2 2025 and -164.32% in Q1 2025.